TRABD2A is a membrane-bound metalloprotease that functions as a negative regulator of Wnt signaling by cleaving the N-terminal region of specific Wnt proteins (WNT3A and WNT5) 1, leading to their oxidation and inactivation through disulfide-bond oligomerization 2. This proteolytic activity is essential for proper head development 2. Beyond its developmental role, TRABD2A exhibits broader biological functions. In immune cells, TRABD2A expression is significantly higher in resting CD4+ T cells compared to activated cells, where it restricts HIV-1 progeny production by degrading the Gag structural precursor at the plasma membrane 3. Reactivation of TRABD2A in activated CD4+ T cells restores HIV-1 resistance 3. Clinically, TRABD2A has emerged as a prognostic biomarker in papillary thyroid carcinoma, associating with T cell proliferation patterns and immune checkpoint response profiles 4. Additionally, TRABD2A expression is modulated by aspirin treatment in normal colon organoids, suggesting involvement in colorectal cancer chemoprevention through Wnt pathway inhibition 5. Changes in TRABD2A expression have also been observed in pathological vascular smooth muscle cells under calcifying conditions 6, indicating roles in vascular biology. These findings position TRABD2A as a multifunctional protease with implications for developmental biology, viral immunity, cancer prevention, and vascular disease.